Fount of Information

TriLink BioTechnologies社 Manipulating CD38 for a Novel Immuno-Oncology Therapy




 Manipulating CD38 for a Novel Immuno-Oncology Therapy

Acute myeloid leukemia (AML) is the most common adult acute leukemia, affecting 80% of this patient population. However, the overall 5-year survival rate remains fairly low, at around 29%. Additional therapies are needed to improve the outcome of this disease.

Immunotherapies are based on manipulating the cells of a patient’s immune system.  A variety of cancer-targeting immunotherapies have already reached the clinic, and one of the oldest is the bone marrow transplant, which has been used for decades. Combined with chemotherapy, bone marrow transplants represent the current standard of care for most AML patients. More recently, chimeric antigen receptor (CAR)-T cell and immune checkpoint inhibitor therapies have caused an explosion of research in this area, leading to the development of Immuno-Oncology as an independent field...


One Experienced Partner from Discovery Through GMP Manufacturing

TriLink offers mRNA researchers the tools they need to go from concept to cure. Build the best-fit solution for every phase of your mRNA program with our experienced project teams and customizable quality grades. Partnering with TriLink for your custom research-grade mRNA enables a seamless transition to GMP when you are ready.  

·     Four ISO class 7 cleanrooms & eight ISO class 8 cleanrooms

·     Meets ICH Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients, Section 19, APIs for use in clinical trials

·     Certified ISO 9001:2015


Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。